HER2+ Breast Cancer | Specialty

Dr Yuan on Dual-Pathway Targeted Strategies in ER+/HER2+ Breast Cancer

October 23rd 2025

Yuan Yuan, MD, PhD, discusses the importance of optimizing dual-pathway targeting in ER-positive, HER2-positive metastatic disease.

Dr Tarantino on De-Escalated THP With/Without Carboplatin in HER2+ Breast Cancer

October 23rd 2025

Paolo Tarantino, MD, PhD, discusses key efficacy data with de-escalated THP with/without carboplatin in HER2-positive breast cancer.

Trastuzumab Rezetecan Displays PFS Benefit Vs Pyrotinib Plus Capecitabine in Pretreated HER2+ Breast Cancer

October 23rd 2025

Trastuzumab rezetecan reduced the risk of disease progression or death by 78% vs pyrotinib plus capecitabine in pretreatedHER2+ advanced breast cancer,

DSMB Recommends Continuation of Phase 3 Study of Bria-IMT in Metastatic Breast Cancer

October 22nd 2025

A data safety monitoring board recommended the continuation of a study of Bria-IMT plus immune checkpoint inhibition in metastatic breast cancer.

DESTINY-Breast09 Subgroup Data Show Clinically Meaningful PFS Benefit T-DXd/Pertuzumab in HER2+ Breast Cancer

October 20th 2025

T-DXd plus pertuzumab generated consistent PFS benefits among HER2+ breast cancer subgroups.

Neoadjuvant T-DXd Plus THP Yields pCR Benefit in High-Risk, HER2+ Early-Stage Breast Cancer

October 18th 2025

Neoadjuvant T-DXd followed by THP improved pathological complete response rate in high-risk, HER2-positive early-stage breast cancer.

T-DXd Improves IDFS and DFS vs T-DM1 in HER2+ Breast Cancer With Residual Invasive Disease

October 18th 2025

T-DXd significantly improved IDFS vs T-DM1 in high-risk, HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy.

Dr Tarantino on the Role of Genomic Testing in HER2+ Breast Cancer

October 16th 2025

Paolo Tarantino, MD, PhD, discusses the role of genomic testing for guiding treatment decisions for patients with HER2-positive breast cancer.

Tucatinib Plus Trastuzumab and Pertuzumab Maintenance Improves PFS in HER2+ Metastatic Breast Cancer

October 14th 2025

Combining tucatinib with trastuzumab and pertuzumab improved PFS as first-line maintenance in patients with HER2-positive metastatic breast cancer.

Dr Tarantino on the CompassHER2 pCR Trial of THP in HER2+ Breast Cancer

October 9th 2025

Paolo Tarantino, MD, PhD, discusses the design and background of the CompassHER2 pCR trial of THP in HER2-positive breast cancer.

Eribulin Plus Pyrotinib Displays Efficacy in Trastuzumab-Resistant HER2+ Breast Cancer

October 9th 2025

Eribulin with pyrotinib was safe and active in patients with HER2-positive advanced breast cancer who were resistant to treatment with trastuzumab.

sNDA Submitted in Japan for T-DXd Plus Pertuzumab in HER2+ Advanced Breast Cancer

October 7th 2025

A new drug application was submitted to Japan’s Ministry of Health, Labour and Welfare for T-DXd plus pertuzumab for HER2-positive breast cancer.

The OncFive: Top Oncology Articles for the Week of 9/28

October 4th 2025

The FDA clears maintenance lurbinectedin combination in lung cancer, T-DxD sBLA in HER2-positive breast cancer is accepted for review, and more.

Dr Yuan on Intracranial Activity With T-DXd Plus Pertuzumab in HER2+ Metastatic Breast Cancer

October 3rd 2025

Yuan Yuan, MD, PhD, reports the intracranial efficacy of T-DXd plus pertuzumab in HER2-positive breast cancer, per results from the DESTINY-Breast12 study.

Dr LeVee on T-DXd in HER2+ Breast Cancer With/Without Brain Metastases

October 3rd 2025

Alexis LeVee, MD, discusses T-DXd in HER2+ breast cancer with or without brain metastases.

Dr Yuan on T-DXd in First-Line HER2+ Advanced/Metastatic Breast Cancer

September 30th 2025

Yuan Yuan, MD, PhD, discusses T-DXd plus pertuzumab in first-line HER2-positive advanced/metastatic breast cancer.

Poll: Vote on the Top Breast Cancer, Hematology Abstracts to Watch at ESMO 2025

September 29th 2025

T-DXd Yields iDFS Improvement vs T-DM1 in High-Risk HER2+ Early Breast Cancer After Neoadjuvant Therapy

September 29th 2025

Trastuzumab deruxtecan demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival vs trastuzumab emtansine in HER2-positive early breast cancer.

The OncFive: Top Oncology Articles for the Week of 9/21

September 27th 2025

Imlunestrant joins the treatment arsenal for ESR1-mutated metastatic breast cancer, T-DXd doublet gets priority review in HER2+ breast cancer, and more.

Breast Cancer Experts: Key ADC Developments and CDK 4/6 Inhibitor Updates Set to Dominate ESMO 2025

September 25th 2025

Ahead of the 2025 ESMO Congress, breast cancer experts share the most anticipated research being presented during the meeting.